Clinical Trial

MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated January 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
Trial Details
NCT Number NCT07045571
Lead Sponsor Yingbin Liu, MD, PhD, FACS
Collaborators: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Changhai Hospital
Conditions Pancreatic Neoplasm, Pancreas Cancer
Enrollment 1,000 participants
Start Date 2022-10-30
Primary Completion 2026-01-22 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2025-07-01